|Bausch Health Companies Inc., of Laval, Quebec||Vyzulta (latanoprostene bunod ophthalmic solution)||PGF2 alpha agonist||Open-angle glaucoma or ocular hypertension||Brazilian Health Regulatory Agency approved the drug|
|Biogen Inc., of Cambridge, Mass.||Tecfidera (dimethyl fumarate)||Activate the nuclear factor (erythroid-derived 2)-like 2 pathway||Relapsing multiple sclerosis||China’s National Medical Products Administration approved the drug|
|Eli Lilly and Co., of Indianapolis||Bamlanivimab||Monoclonal antibody targeting SARS-CoV-2||COVID-19||Company requested FDA revoke the emergency use authorization for the drug as a monotherapy due to emergence of variants|
|Oncopeptides AB, of Stockholm||Melflufen (melphalan flufenamide)||Peptide-drug conjugate targeting aminopeptidases||Relapsed/refractory multiple myeloma||Submitted conditional marketing authorization to the EMA|
|Shenzhen Chipscreen Biosciences Co. Ltd., of Shenzhen||Chiauranib (CS-2164)||Aurora B/VEGFRs/CSF1R inhibitor||Small-cell lung cancer||FDA cleared the IND for a phase Ib/II study of chiauranib as a monotherapy in 24 to 36 patients|
For more information about individual companies and/or products, see Cortellis.